186 related articles for article (PubMed ID: 23459285)
1. Unapproved drugs--the drug information pharmacists' perspective.
Giouroukakis M; Dryer M
J Pharm Pract; 2013 Apr; 26(2):112-9. PubMed ID: 23459285
[TBL] [Abstract][Full Text] [Related]
2. Unapproved prescription cough, cold, and allergy drug products: recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications.
Ostroff C; Lee CE; McMeekin J
Chest; 2011 Aug; 140(2):295-300. PubMed ID: 21813527
[TBL] [Abstract][Full Text] [Related]
3. Unapproved drugs in the United States and the Food and Drug Administration.
Nasr A; Lauterio TJ; Davis MW
Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
[TBL] [Abstract][Full Text] [Related]
4. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.
Gupta R; Dhruva SS; Fox ER; Ross JS
J Manag Care Spec Pharm; 2017 Oct; 23(10):1066-1076. PubMed ID: 28944731
[TBL] [Abstract][Full Text] [Related]
5. FDA policy on unapproved drug products: past, present, and future.
Chhabra R; Kremzner ME; Kiliany BJ
Ann Pharmacother; 2005; 39(7-8):1260-4. PubMed ID: 15956239
[TBL] [Abstract][Full Text] [Related]
6. The FDA takes action against unapproved drugs.
Meadows M
FDA Consum; 2007; 41(1):34-5. PubMed ID: 17342837
[TBL] [Abstract][Full Text] [Related]
7. Pharmacists' evaluations of the nonprescription availability of metaproterenol, cimetidine, ibuprofen, and nystatin.
Madhavan S; Schondelmeyer SW
Am J Hosp Pharm; 1989 Dec; 46(12):2486-92. PubMed ID: 2603883
[TBL] [Abstract][Full Text] [Related]
8. Estimating the Impact of Food and Drug Administration's Unapproved Drug Initiative on Drug Prices and Sales.
Sharma D; Schumock GT; Saffore CD; Albert Edwards S; Walton SM
Ther Innov Regul Sci; 2020 Mar; 54(2):424-430. PubMed ID: 32072591
[TBL] [Abstract][Full Text] [Related]
9. Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs.
Pediatrics; 1996 Jul; 98(1):143-5. PubMed ID: 8668390
[TBL] [Abstract][Full Text] [Related]
10. Review of purchases of unapproved medications by the Veterans Health Administration.
Carico RL; Emmendorfer TR; Aspinall SL; Mizah MT; Good CB
Am J Health Syst Pharm; 2019 Nov; 76(23):1934-1943. PubMed ID: 31628792
[TBL] [Abstract][Full Text] [Related]
11. Community pharmacists' understanding and perceptions of FDA therapeutic equivalence standards.
Euen BJ; Fadda HM
Res Social Adm Pharm; 2019 Jan; 15(1):77-83. PubMed ID: 29567088
[TBL] [Abstract][Full Text] [Related]
12. Clinical and regulatory features of drugs not initially approved by the FDA.
Wang B; Avorn J; Kesselheim AS
Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
[TBL] [Abstract][Full Text] [Related]
13. What's next after 50 years of psychiatric drug development: an FDA perspective.
Laughren TP
J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
[TBL] [Abstract][Full Text] [Related]
14. The debate on FDA reform: a view from the U.S. Senate. Food and Drug Administration.
Baker R
BETA; 1995 Sep; ():41-4. PubMed ID: 11362892
[TBL] [Abstract][Full Text] [Related]
15. FDA reform in Congress: AIDS community absent. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Apr; (no 220):4-5. PubMed ID: 11362320
[TBL] [Abstract][Full Text] [Related]
16. Canadian and US drug approval times and safety considerations.
Rawson NS; Kaitin KI
Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
[TBL] [Abstract][Full Text] [Related]
17. Examination of pharmacists' intention to report serious adverse drug events (ADEs) to the FDA using the theory of planned behavior.
Gavaza P; Brown CM; Lawson KA; Rascati KL; Wilson JP; Steinhardt M
Res Social Adm Pharm; 2011 Dec; 7(4):369-82. PubMed ID: 21272531
[TBL] [Abstract][Full Text] [Related]
18. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
[TBL] [Abstract][Full Text] [Related]
19. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
20. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
